Operating Expenses Summary of Virbac SA

Virbac SA's latest annual operating expenses in 2023 was 250.68 Million EUR , down -59.08% from previous year.
Virbac SA's latest quarterly operating expenses in 2024 Q2 was 187.14 Million EUR , down 0.0% from previous quarter.
Virbac SA reported a annual operating expenses of 612.7 Million EUR in annual operating expenses 2022, up 12.2% from previous year.
Virbac SA reported a annual operating expenses of 546.08 Million EUR in annual operating expenses 2021, up 10.82% from previous year.
Virbac SA reported a quarterly operating expenses of 187.14 Million EUR for 2024 Q2, down 0.0% from previous quarter.
Virbac SA reported a quarterly operating expenses of 250.68 Million EUR for 2023 FY, down -59.08% from previous quarter.

Annual Operating Expenses Chart of Virbac SA (2023 - 2002)

Historical Annual Operating Expenses of Virbac SA (2023 - 2002)

Year	Operating Expenses	Operating Expenses Growth
2023	250.68 Million EUR	-59.08%
2022	612.7 Million EUR	12.2%
2021	546.08 Million EUR	10.82%
2020	492.77 Million EUR	-4.76%
2019	517.42 Million EUR	3.74%
2018	498.76 Million EUR	1.18%
2017	492.95 Million EUR	-2.09%
2016	503.46 Million EUR	-1.87%
2015	513.06 Million EUR	22.46%
2014	418.95 Million EUR	5.69%
2013	396.4 Million EUR	4.5%
2012	379.34 Million EUR	93.5%
2011	196.04 Million EUR	-35.36%
2010	303.3 Million EUR	17.75%
2009	257.58 Million EUR	5.62%
2008	243.88 Million EUR	0.72%
2007	242.14 Million EUR	83.88%
2006	131.68 Million EUR	4.64%
2005	125.85 Million EUR	-39.67%
2004	208.59 Million EUR	-37.46%
2003	333.55 Million EUR	-1.28%
2002	337.88 Million EUR	0.0%

Year	Operating Expenses	Operating Expenses Growth
2024 Q1	187.14 Million EUR	11.88%
2024 Q2	187.14 Million EUR	0.0%
2023 FY	250.68 Million EUR	-59.08%
2023 Q2	109 Million EUR	-25.64%
2023 Q3	172.55 Million EUR	58.3%
2023 Q4	167.26 Million EUR	-3.06%
2023 Q1	146.58 Million EUR	6.71%
2022 Q1	146.07 Million EUR	17.53%
2022 Q2	116.57 Million EUR	-20.2%
2022 Q3	163.5 Million EUR	40.25%
2022 Q4	137.36 Million EUR	-15.99%
2022 FY	612.7 Million EUR	12.2%
2021 Q4	124.29 Million EUR	-13.93%
2021 FY	546.08 Million EUR	10.82%
2021 Q2	93.98 Million EUR	-25.73%
2021 Q1	126.54 Million EUR	34.52%
2021 Q3	144.41 Million EUR	53.66%
2020 FY	492.77 Million EUR	-4.76%
2020 Q2	83.66 Million EUR	-33.44%
2020 Q1	125.7 Million EUR	26.95%
2020 Q4	94.06 Million EUR	2.34%
2020 Q3	91.91 Million EUR	9.86%
2019 Q2	130.58 Million EUR	0.0%
2019 Q4	99.02 Million EUR	-26.33%
2019 FY	517.42 Million EUR	3.74%
2019 Q3	134.4 Million EUR	2.93%
2019 Q1	130.58 Million EUR	-1.22%
2018 Q3	132.19 Million EUR	4.83%
2018 FY	498.76 Million EUR	1.18%
2018 Q2	126.1 Million EUR	0.0%
2018 Q1	126.1 Million EUR	4.0%
2018 Q4	132.19 Million EUR	0.0%
2017 Q3	121.26 Million EUR	-4.89%
2017 Q2	127.49 Million EUR	0.0%
2017 Q4	121.26 Million EUR	0.0%
2017 FY	492.95 Million EUR	-2.09%
2017 Q1	127.49 Million EUR	3.39%
2016 Q4	123.31 Million EUR	0.0%
2016 Q1	126.57 Million EUR	-0.72%
2016 FY	503.46 Million EUR	-1.87%
2016 Q3	123.31 Million EUR	-2.58%
2016 Q2	126.57 Million EUR	0.0%
2015 Q2	136.29 Million EUR	0.0%
2015 FY	513.06 Million EUR	22.46%
2015 Q4	127.48 Million EUR	0.0%
2015 Q3	127.48 Million EUR	-6.47%
2015 Q1	136.29 Million EUR	23.7%
2014 Q1	101.32 Million EUR	0.12%
2014 FY	418.95 Million EUR	5.69%
2014 Q3	110.18 Million EUR	8.75%
2014 Q4	110.18 Million EUR	0.0%
2014 Q2	101.32 Million EUR	0.0%
2013 Q1	101.11 Million EUR	0.0%
2013 FY	396.4 Million EUR	4.5%
2013 Q3	101.19 Million EUR	0.08%
2013 Q2	101.11 Million EUR	0.0%
2013 Q4	101.19 Million EUR	0.0%
2012 FY	379.34 Million EUR	93.5%
2011 FY	196.04 Million EUR	-35.36%
2010 FY	303.3 Million EUR	17.75%
2009 FY	257.58 Million EUR	5.62%
2008 FY	243.88 Million EUR	0.72%
2007 FY	242.14 Million EUR	83.88%
2006 FY	131.68 Million EUR	4.64%
2005 FY	125.85 Million EUR	-39.67%
2004 FY	208.59 Million EUR	-37.46%
2003 FY	333.55 Million EUR	-1.28%
2002 FY	337.88 Million EUR	0.0%

Peer Operating Expenses Comparison of Virbac SA

Name	Operating Expenses	Operating Expenses Difference
AstraZeneca PLC	29.57 Billion USD	99.152%
Bristol-Myers Squibb Company PFD CONV 2	17.07 Billion USD	98.531%
CSPC Pharmaceutical Group Limited	2.14 Billion USD	88.324%
Clarus Therapeutics Holdings, Inc.	50.96 Million USD	-391.844%
Novartis AG	24.87 Billion USD	98.992%
PT Kalbe Farma Tbk.	11823.24 Billion USD	99.998%

Global Stocks Search

Virbac SA (VRBCF)

Operating Expenses Summary of Virbac SA

Annual Operating Expenses Chart of Virbac SA (2023 - 2002)

Historical Annual Operating Expenses of Virbac SA (2023 - 2002)

Peer Operating Expenses Comparison of Virbac SA